New targets and old therapies for arterial hypertension
https://doi.org/10.21518/2079-701X-2019-5-46-52
Abstract
The article discusses approaches to the choice of antihypertensive drugs, which may be based on the adoption and implementation of new clinical guidelines for the management of patients with arterial hypertension. This paper provides data on the efficacy and safety of candesartan, an antihypertensive drug, which advantages were identified during a large number of randomized clinical trials. It discusses the recently published data on the effectiveness of more intensive regimens of antihypertensive therapy to reduce the risk of moderate cognitive impairment in patients with arterial hypertension. In this regard, the authors provide data of the previously completed studies, which showed the effect of candesartan on the rate of cognitive decline in patients with arterial hypertension in the elderly and senile age. The features of the pharmacological characteristics of candesaratan that can remotely explain its clinical efficacy are considered. The data of experimental studies of candesartan in animals, which contribute to the concept of the possible effects of candesartan, are presented.
About the Authors
S. R. Gilyarevsky
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Gilyarevsky Sergei Rudzherovich – Dr. of Sci. (Med.), Professor of Chair for Clinical Pharmacology and Therapy.
125993, Russia, Moscow, Barrikadnaya St., 2/1, Bldg. 1.
N. G. Bendeliani
Coronary and Vascular Surgery Institute of the Federal State Budgetary Institution «Bakulev National Medical Research Center for Cardiovascular Surgery» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Bendeliani Nana Georgievna – Dr. of Sci. (Med.), Senior Researcher, Scientific Advisory Department.
119049 Russia, Moscow, Volokolamskoe Shosse, 8, Bldg. 4.
M. V. Golshmid
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Golshmid Maria Vladimirovna – Cand. of Sci. (Med.), Associate Professor of Chair for Clinical Pharmacology and Therapy.
125993, Russia, Moscow, Barrikadnaya St., 2/1, Bldg. 1.
G. Yu. Zakharova
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Zakharova Galina Yurievna – Cand. of Sci. (Med.), Associate Professor of Chair for Clinical Pharmacology and Therapy.
125993, Russia, Moscow, Barrikadnaya St., 2/1, Bldg. 1.
I. M. Kuzmina
State Budgetary Healthcare Institution of Moscow «Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscow».
Russian Federation
Russian Federation
Kuzmina Irina Mikhailovna – Cand. of Sci. (Med.), Leading Researcher of Emergency Cardiology Department.
129090, Moscow, B. Sukharevskaya Pl., 3, Bldg. 21.
I. I. Sinitsina
Federal State Budgetary Educational Institution of Further Professional Education «Russian Medical Academy of Continuing Professional Education» of the Ministry of Health of the Russian Federation.
Russian Federation
Russian Federation
Sinitsina Irina Ivanovna – Dr. of Sci. (Med.), Professor of Chair for Clinical Pharmacology and Therapy.
125993, Russia, Moscow, Barrikadnaya St., 2/1, Bldg. 1.
References
1. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ ehy339.
2. Whelton P.K., Carey R.M., Aronow W.S. et al. 2017. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71:e13-e115. doi: 10.1161/ HYP.0000000000000065. 2017.
3. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373:2103-2116.
4. Phillips R.A., Xu J., Peterson L.E. et al. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. J Am Coll Cardiol. 2018;71:1601-1610. doi: 10.1016/j.jacc.2018.01.074.
5. Julius S., Nesbitt S.D., Egan B.M. et al. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med. 2006;354:1685-1697.
6. Lithell H., Hansson L., Skoog I. et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hyperens. 2003;21:875-886.
7. Skoog I., Lithell H., Hansson L. et al. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens. 2005;18:1052-1059.
8. Levi Marpillat N., Macquin-Mavier I., Tropeano A.I. et al. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31:1073-1082.
9. The SPRINT MIND Investigators for the SPRINT Research Group. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. A Randomized Clinical Trial. JAMA. 2019;321(6):553561. doi: 10.1001/jama.2018.21442.
10. McMurray J., Ostergren J., Pfeffer M. et al. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail. 2003;5(3):261-270.
11. Swedberg K., Pfeffer M., Granger C. et al. Candesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): Rationale and design. J Cardiac Failure. 1999;5:276-282.
12. Pool-Wilson P. Official critique: CHARM results «Do not disappoint». Available at: www.medscape.com.
13. Cernes R., Mashavi M., Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag. 2011;7:749-759. doi: 10.2147/VHRM.S22591.
14. Van Liefde I., Vauquelin G. Sartan-AT1 receptor interactions: in vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302:237-243.
15. Morsing P., Adler G., Brandt-Eliasson U. et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension. 1999;33:1406-1413.
16. Nasser M., Chedid P., Salami A. et al. Dataset on significant role of Candesartan on cognitive functions in rats having memory impairment induced by electromagnetic waves. Data Brief. 2018 Nov 26;21:2390-2394. doi: 10.1016/j.dib.2018.11.106. eCollection 2018 Dec.
17. Trofimiuk E., Wielgat P., Braszko J.J. Candesartan, angiotensin II type 1 receptor blocker is able to relieve age-related cognitive impairment. Pharmacol Rep. 2018;70:87-92. doi: 10.1016/j.pharep.2017.07.016.
Review
For citations:
Gilyarevsky SR, Bendeliani NG, Golshmid MV, Zakharova GY, Kuzmina IM, Sinitsina II. New targets and old therapies for arterial hypertension. Meditsinskiy sovet = Medical Council. 2019;(5):46-52. (In Russ.) https://doi.org/10.21518/2079-701X-2019-5-46-52
Views:
875
Email this article 